Complete financial analysis of BioNxt Solutions Inc. (XPHYF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioNxt Solutions Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Mitsubishi Heavy Industries, Ltd. (7011.T) Income Statement Analysis – Financial Results
- Tanke, Inc. (TNKE) Income Statement Analysis – Financial Results
- Liberty Bancshares, Inc. (Ada, OH) (LBSI) Income Statement Analysis – Financial Results
- Sitka Gold Corp. (SITKF) Income Statement Analysis – Financial Results
- High Liner Foods Incorporated (HLNFF) Income Statement Analysis – Financial Results
BioNxt Solutions Inc. (XPHYF)
About BioNxt Solutions Inc.
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Wall Street in the red again this week
XPhyto Therapeutics adds top-level executive talent to lead commercialization of its Covid-ID Lab
XPhyto adds Top-Level Executive Talent to its Global Operations
XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Recent European Approval of 25-Minute COVID-19 PCR Test
XPhyto Therapeutics announces EU approval for coronavirus test
XPhyto Therapeutics and German partner announce successful quality certification for the Covid-ID Lab
XPhyto Partner Receives ISO Certification for 25-Minute COVID-19 RT-PCR Test
Emerging Markets Report: A Psychedelic Story
XPhyto Therapeutics completes corporate rebranding, launches new website
XPhyto Completes Corporate Rebranding and Launches New Website
Source: https://incomestatements.info
Category: Stock Reports